Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Kentucky: - King's Daughter's Medical Center — Ashland, Kentucky
- CommonSpirit Saint Joseph Hospital - Bardstown — Bardstown, Kentucky
- Baptist Health Corbin — Corbin, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Baptist Health Hardin — Elizabethtown, Kentucky
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Kentucky: - King's Daughter's Medical Center — Ashland, Kentucky
- CommonSpirit Saint Joseph Hospital - Bardstown — Bardstown, Kentucky
- CommonSpirit Saint Joseph Medical Center - East Lexington — Lexington, Kentucky
- Owensboro Health Mitchell Memorial Cancer Center — Owensboro, Kentucky
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Kentucky: - Baptist Health Hardin — Elizabethtown, Kentucky
- University of Kentucky/Markey Cancer Center — Lexington, Kentucky
- The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
- Norton Brownsboro Hospital and Medical Campus — Louisville, Kentucky
- UofL Health Medical Center Northeast — Louisville, Kentucky
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…
Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in Kentucky: - Research Site — Fort Mitchell, Kentucky
- Research Site — Lexington, Kentucky
- Research Site — Louisville, Kentucky
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Kentucky: - Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0044) — Edgewood, Kentucky
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in Kentucky: - Research Site — Louisville, Kentucky
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Kentucky: - Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0053) — Edgewood, Kentucky
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Sites in Kentucky: - Baptist Health Lexington ( Site 0050) — Lexington, Kentucky
- Baptist Health Hamburg ( Site 0071) — Lexington, Kentucky
Phase 1 Recruiting Industry
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Sponsor: Clasp Therapeutics, Inc.
NCT ID: NCT06778863
Sites in Kentucky: - University of Kentucky Markey Cancer Center — Lexington, Kentucky
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Kentucky: - Flaget Memorial Hospital — Bardstown, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
- Saint Joseph London — London, Kentucky
- Saint Joseph Mount Sterling — Mount Sterling, Kentucky
- Mercy Health - Paducah Cancer Center — Paducah, Kentucky
Phase 4 Recruiting Industry
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…
Sponsor: AstraZeneca
NCT ID: NCT07357597
Sites in Kentucky: - Research Site — Elizabethtown, Kentucky
- Research Site — Lexington, Kentucky
- Research Site — Lexington, Kentucky
- Research Site — Louisville, Kentucky
Recruiting Industry
The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhance…
Sponsor: EXoPERT
NCT ID: NCT07186296
Sites in Kentucky: - Lexington VA Healthcare System — Lexington, Kentucky
- KCTL — Louisville, Kentucky